Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (37)
Clifford TeBay, Adam P. Hill & Monique J. Windley. (2022) Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. Biophysical Reviews 14:1, pages 353-367.
Crossref
Crossref
Yun Chang, Ya-nan Li, Rui Bai, Fujian Wu, Shuhong Ma, Amina Saleem, Siyao Zhang, Youxu Jiang, Tao Dong, Tianwei Guo, Chengwen Hang, Wen-jing Lu, Hongfeng Jiang & Feng Lan. (2021) hERG-deficient human embryonic stem cell-derived cardiomyocytes for modelling QT prolongation. Stem Cell Research & Therapy 12:1.
Crossref
Crossref
He Cai, Hongbo Men, Pengyu Cao & Yang Zheng. (2021) Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). Experimental and Therapeutic Medicine 22:6.
Crossref
Crossref
Tingting Pan, Min Shen, Jiayan Shi, Juewei Ning, Fengyu Su, Jianxiang Liao & Yanqing Tian. (2021) Intracellular potassium ion fluorescent nanoprobes for functional analysis of hERG channel via bioimaging. Sensors and Actuators B: Chemical 345, pages 130450.
Crossref
Crossref
Tae Rim Kim, Hyeon-Young Kim, In-Hyeon Kim, Ki Cheon Kim, Youngho Ko, Jun Hong Park, Sungil Yun, In-Chul Lee, Sung-Hwan Kim & Han-Oh Park. (2021) Safety pharmacology of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle platform. Toxicology Reports 8, pages 839-845.
Crossref
Crossref
Yun Zhao, Shuting Ma, Miaomiao Cao & Chaofeng Sun. (2020) G604S-HERG mutation in LQT2 leads to autophagy via the UPR-related pathway. Journal of Biosciences 45:1.
Crossref
Crossref
Lynnetta M. WattsEwa Karwatowska-ProkopczukEunju HurhVeronica J. AlexanderKristin BaloghLouis O'DeaRichard S. GearySotirios Tsimikas. (2020)
Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting
APOC3
mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
. Nucleic Acid Therapeutics 30:4, pages 198-206.
Crossref
Crossref
István Baczkó, Tibor Hornyik, Michael Brunner, Gideon Koren & Katja E. Odening. (2020) Transgenic Rabbit Models in Proarrhythmia Research. Frontiers in Pharmacology 11.
Crossref
Crossref
Wei Yin & Mark Rogge. (2019)
Targeting
RNA
: A Transformative Therapeutic Strategy
. Clinical and Translational Science 12:2, pages 98-112.
Crossref
Crossref
Eunjung Park, Gary A Gintant, Daoqin Bi, Devi Kozeli, Syril D Pettit, Jennifer B Pierson, Matthew Skinner, James Willard, Todd Wisialowski, John Koerner & Jean-Pierre Valentin. (2018) Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. British Journal of Pharmacology 175:4, pages 606-617.
Crossref
Crossref
Logan C. Macdonald, Robin Y. Kim, Harley T. Kurata & David Fedida. (2018) Probing the molecular basis of hERG drug block with unnatural amino acids. Scientific Reports 8:1.
Crossref
Crossref
Yihong Zhang, Charlotte K. Colenso, Aziza El Harchi, Hongwei Cheng, Harry J. Witchel, Chris E. Dempsey & Jules C. Hancox. (2016) Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking. Biochemical Pharmacology 113, pages 24-35.
Crossref
Crossref
Annarosa Arcangeli & Andrea Becchetti. (2015) Novel perspectives in cancer therapy: Targeting ion channels. Drug Resistance Updates 21-22, pages 11-19.
Crossref
Crossref
John Mitcheson & Annarosa Arcangeli. 2014. Ion Channel Drug Discovery. Ion Channel Drug Discovery
258
296
.
Peter Schmidtke, Marine Ciantar, Isabelle Theret & Pierre Ducrot. (2014) Dynamics of hERG Closure Allow Novel Insights into hERG Blocking by Small Molecules. Journal of Chemical Information and Modeling 54:8, pages 2320-2333.
Crossref
Crossref
Tae-Won Kim, Ki-Suk Kim, Joung-Wook Seo, Shin-Young Park & Scott P. Henry. (2014) Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. Journal of Pharmacological and Toxicological Methods 69:1, pages 49-60.
Crossref
Crossref
Douglas B. Kell, Paul D. Dobson, Elizabeth Bilsland & Stephen G. Oliver. (2013) The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discovery Today 18:5-6, pages 218-239.
Crossref
Crossref
Rashmi R. Shah & Ihor Gussak. 2013. Electrical Diseases of the Heart. Electrical Diseases of the Heart
73
122
.
Serdar Durdagi, Sumukh Deshpande, Henry J Duff & Sergei Y. Noskov. (2012) Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding. Journal of Chemical Information and Modeling 52:10, pages 2760-2774.
Crossref
Crossref
Renee Aspiotis, Austin Chen, Elizabeth Cauchon, Daniel Dub?Jean-Pierre Falgueyret, S?bastien Gagn?Michel Gallant, Erich L. Grimm, Robert Houle, H?l?ne Juteau, Patrick Lacombe, S?bastien Lalibert?Jean-Fran?ois L?vesque, Dwight MacDonald, Dan McKay, M. David Percival, Patrick Roy, Stephen M. Soisson & Tom Wu. (2011) The discovery and synthesis of potent zwitterionic inhibitors of renin. Bioorganic & Medicinal Chemistry Letters 21:8, pages 2430-2436.
Crossref
Crossref
Graham F. Smith. 2011. Progress in Medicinal Chemistry Volume 50. Progress in Medicinal Chemistry Volume 50
1
47
.
E. Kevin HeistJeremy N. Ruskin. (2010) Drug-Induced Arrhythmia. Circulation 122:14, pages 1426-1435.
Crossref
Crossref
Annarosa Arcangeli & Andrea Becchetti. (2010) New Trends in Cancer Therapy: Targeting Ion Channels and Transporters. Pharmaceuticals 3:4, pages 1202-1224.
Crossref
Crossref
Attila S. Farkas & Stanley Nattel. (2010) Minimizing Repolarization-Related Proarrhythmic Risk in Drug Development and Clinical Practice. Drugs 70:5, pages 573-603.
Crossref
Crossref
Robert M Wallis. (2010) Integrated risk assessment and predictive value to humans of non‐clinical repolarization assays. British Journal of Pharmacology 159:1, pages 115-121.
Crossref
Crossref
Igor Shamovsky, Chris de Graaf, Lisa Alderin, Malena Bengtsson, Håkan Bladh, Lena Börjesson, Stephen ConnollyHazel J. DykeMarco van den HeuvelHenrik Johansson, Bo-Göran Josefsson, Anna Kristoffersson, Tero Linnanen, Annea Lisius, Roope MännikköBo Nordén, Steve PriceLena Ripa, Didier Rognan, Alexander Rosendahl, Marco Skrinjar & Klaus Urbahns. (2009) Increasing Selectivity of CC Chemokine Receptor 8 Antagonists by Engineering Nondesolvation Related Interactions with the Intended and Off-Target Binding Sites. Journal of Medicinal Chemistry 52:23, pages 7706-7723.
Crossref
Crossref
Katja Hansen, Fabian Rathke, Timon Schroeter, Georg Rast, Thomas Fox, Jan M. Kriegl & Sebastian Mika. (2009) Bias-Correction of Regression Models: A Case Study on hERG Inhibition. Journal of Chemical Information and Modeling 49:6, pages 1486-1496.
Crossref
Crossref
Jinghai J. Xu & Li J. Yu. 2008. Drug Efficacy, Safety, and Biologics Discovery. Drug Efficacy, Safety, and Biologics Discovery
1
28
.
Joey L. Methot, Christopher L. Hamblett, Dawn M. Mampreian, Joon Jung, Andreas Harsch, Alexander A. Szewczak, William K. Dahlberg, Richard E. Middleton, Bethany Hughes, Judith C. Fleming, Hongmei Wang, Astrid M. Kral, Nicole Ozerova, Jonathan C. Cruz, Brian Haines, Melissa Chenard, Candia M. Kenific, J. Paul Secrist & Thomas A. Miller. (2008) SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorganic & Medicinal Chemistry Letters 18:23, pages 6104-6109.
Crossref
Crossref
Hugo M. Vargas, Alan S. Bass, Alexander Breidenbach, Hal S. Feldman, Gary A. Gintant, Alexander R. Harmer, Bronagh Heath, Peter Hoffmann, Armando Lagrutta, Derek Leishman, Nick McMahon, Scott Mittelstadt, Liudmila Polonchuk, Michael K. Pugsley, Joseph J. Salata & Jean-Pierre Valentin. (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. Journal of Pharmacological and Toxicological Methods 58:2, pages 72-76.
Crossref
Crossref
John S. Mitcheson. (2008) hERG Potassium Channels and the Structural Basis of Drug-Induced Arrhythmias. Chemical Research in Toxicology 21:5, pages 1005-1010.
Crossref
Crossref
Igor Shamovsky, Stephen Connolly, Laurent David, Svetlana Ivanova, Bo Nordén, Brian Springthorpe & Klaus Urbahns. (2008) Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships. Journal of Medicinal Chemistry 51:5, pages 1162-1178.
Crossref
Crossref
Sarah Dalibalta & John S. Mitcheson. 2008. Antitargets. Antitargets
89
108
.
Fabrizio De Ponti. 2008. Antitargets. Antitargets
53
88
.
Stephen R. Johnson, Hongwen Yue, Mary Lee Conder, Hong Shi, Arthur M. Doweyko, John Lloyd & Paul Levesque. (2007) Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR. Bioorganic & Medicinal Chemistry 15:18, pages 6182-6192.
Crossref
Crossref
Willi Suter. (2007) Improving Decision-Making in Drug Development Using In Vitro Toxicology Screening. International Journal of Pharmaceutical Medicine 21:5, pages 347-355.
Crossref
Crossref
S. Bhavani, A. Nagargadde, A. Thawani, V. Sridhar & N. Chandra. (2006) Substructure-Based Support Vector Machine Classifiers for Prediction of Adverse Effects in Diverse Classes of Drugs. Journal of Chemical Information and Modeling 46:6, pages 2478-2486.
Crossref
Crossref